AJP-Heart and Circulatory Podcasts

What do we know about the relationship between uncoupling proteins (UCP) and myocardial energetics, as well as UCP and ROS production? This podcast explores these topics and more in Associate Editor Gary Lopaschuk’s interview with lead author Cevher Ozcan (University at Buffalo) and expert Hossein Ardehali (Northwestern University) on the work by Ozcan and her colleagues. What is the role of UCP3 in ischemia reperfusion injury, arrhythmia, and preconditioning? What human diseases implicate mutations in UCP3 and other uncoupling proteins in their pathology? Listen to learn more.

Cevher Ozcan, Monica Palmeri, Tamas L. Horvath, Kerry S. Russell, and Raymond R. Russell III Role of uncoupling protein 3 in ischemia-reperfusion injury, arrhythmias, and preconditioning Am J Physiol Heart Circ Physiol, published online March 1, 2013, doi: 10.1152/ajpheart.00592.2012.

Listen Now:

 Standard Podcasts [00:11:17m]: Play Now | Play in Popup | Download | Embeddable Player | Hits (Loading)

How does the gut microbiome impact on myocardial energy substrate metabolism? In part one of our two-part podcast on the Review article by Cotter et al, Associate Editor Christine Des Rosiers interviews lead author Peter Crawford (Washington University in St. Louis) and renowned metabolism expert Heinrich Taegtmeyer (University of Texas Medical School). Building on Crawford and colleagues' seminal work published in 2009 on ketone body metabolism using a unique experimental mouse model, which is germ free, we discuss the broad topic of integrated intermediary metabolism. What is the link between the gut microbiome, ketone body metabolism and cardiac physiology? Listen and learn.

David G. Cotter, Rebecca C. Schugar, and Peter A. Crawford Ketone body metabolism and cardiovascular disease Am J Physiol Heart Circ Physiol, published online February 8, 2013, doi: 10.1152/ajpheart.00646.2012.

Listen Now:

 Standard Podcasts [00:08:02m]: Play Now | Play in Popup | Download | Embeddable Player | Hits (Loading)

What happens when myocardium are exposed to chronic states of ketosis? In part two of our podcast on the Review article by Cotter et al, Associate Editor Christine Des Rosiers continues the discussion with lead author Peter Crawford (Washington University in St. Louis) and renowned metabolism expert Heinrich Taegtmeyer (University of Texas Medical School) about the adaptation of the myocardium to chronic ketosis. We explore how the heart protects itself from an overabundance of ketone bodies by down regulating key regulatory enzymes in ketone body metabolism. What new experimental models are being developed to study the targeted inactivation of the SCOT enzyme, which may help us understand how the heart protects against fuel toxicity? Listen now.

David G. Cotter, Rebecca C. Schugar, and Peter A. Crawford Ketone body metabolism and cardiovascular disease Am J Physiol Heart Circ Physiol, published online February 8, 2013, doi: 10.1152/ajpheart.00646.2012.

Listen Now:

 Standard Podcasts [09:42m]: Play Now | Play in Popup | Download | Embeddable Player | Hits (Loading)

Assessment of cardiac mitochondrial function in patients with chronic ischemic heart disease is rarely undertaken, but ultimately these measurements provide the final word in our understanding of the pathology of myocardial bioenergetics. In this new podcast, Editor in Chief William Stanley interviews lead author Flemming Dela (University of Copenhagen) and expert Ethan Anderson (East Carolina University) about the clinical studies by Stride et al. Listen as we gain new insights into the challenges of obtaining samples from human ventricle tissue, and discuss the experimental hurdles faced by researchers in this field. Will the next steps uncover new ways to manipulate mitochondria to lessen ischemia injury? Listen and find out.

Nis Stride, Steen Larsen, Martin Hey-Mogensen, Christina Neigaard Hansen, Clara Prats, Daniel Steinbrüchel, Lars Køber, and Flemming Dela Impaired Mitochondrial Function in Chronically Ischemic Human Heart Am J Physiol Heart Circ Physiol, published online March 29, 2013, doi: 10.1152/ajpheart.00991.2012.

Listen Now:

 Standard Podcasts [00:10:33m]: Play Now | Play in Popup | Download | Embeddable Player | Hits (Loading)

How can one monogenic defect—a mutation of the structural protein ankyrin-B—give rise to multiple disparate phenotypes across the heart? The new work by Wolf et al examines this very question. Associate Editor Igor Efimov interviews lead author Thomas Hund (Ohio State University) and expert Natalia Trayanova (Johns Hopkins University) in our latest podcast, which explores the multi-scale computer model created by Hund and his colleagues to study ankyrin-B mutation and its effect on sinus node dysfunction. Does Hund make the case for using an integrative, rather than reductionist, approach to studying cardiac arrhythmias? Listen and learn.

Roseanne M. Wolf, Patric Glynn, Seyed Hashemi, Keyan Zarei, Colleen C. Mitchell, Mark E. Anderson, Peter J. Mohler, and Thomas J. Hund Atrial Fibrillation and Sinus Node Dysfunction in Human Ankyrin-B Syndrome: A Computational Analysis Am J Physiol Heart Circ Physiol, published online February 22, 2013, doi: 10.1152/ajpheart.00734.2012.

Listen Now:

 Standard Podcasts [00:10:40m]: Play Now | Play in Popup | Download | Embeddable Player | Hits (Loading)

Reducing infarct size to prevent ischemic heart failure in patients with acute myocardial infarction is a known challenge for clinical cardiologists, and few drugs meet this challenge. In our new podcast Associate Editor Masafumi Kitakaze interviews lead author Shinya Minatoguchi (Gifu University Graduate School of Medicine, Gifu, Japan) and expert Tetsuji Miura (Sapporo Medical University School of Medicine, Sapporo, Japan) about the innovative new work by Yamada et al which used liposomal erythropoietin therapy to reduce infarct size in a rabbit heart model. Can this relatively non-invasive drug delivery method become an effective way to reduce infarct size in acute MI human patients? Listen now.

Yoshihisa Yamada, Hiroyuki Kobayashi, Masamitsu Iwasa, Shohei Sumi, Hiroaki Ushikoshi, Takuma Aoyama,
Kazuhiko Nishigaki, Genzou Takemura, Takako Fujiwara, Hisayoshi Fujiwara, Makoto Kiso, and Shinya Minatoguchi Postinfarct active cardiac-targeted delivery of erythropoietin by liposomes with sialyl Lewis X repairs infarcted myocardium in rabbits Am J Physiol Heart Circ Physiol, published online February 15, 2013, doi: 10.1152/ajpheart.00707.2012.

Listen Now:

 Standard Podcasts [00:08:15m]: Play Now | Play in Popup | Download | Embeddable Player | Hits (Loading)

NEW! In this JAPANESE language podcast, Associate Editor Masafumi Kitakaze interviews lead author Shinya Minatoguchi (Gifu University Graduate School of Medicine, Gifu, Japan) and expert Tetsuji Miura (Sapporo Medical University School of Medicine, Sapporo, Japan) about the innovative new work by Yamada et al which used liposomal erythropoietin therapy to reduce infarct size in a rabbit heart model. Can this relatively non-invasive drug delivery method become an effective way to reduce infarct size in acute MI human patients? Listen now.

Yoshihisa Yamada, Hiroyuki Kobayashi, Masamitsu Iwasa, Shohei Sumi, Hiroaki Ushikoshi, Takuma Aoyama,
Kazuhiko Nishigaki, Genzou Takemura, Takako Fujiwara, Hisayoshi Fujiwara, Makoto Kiso, and Shinya Minatoguchi Postinfarct active cardiac-targeted delivery of erythropoietin by liposomes with sialyl Lewis X repairs infarcted myocardium in rabbits Am J Physiol Heart Circ Physiol, published online February 15, 2013, doi: 10.1152/ajpheart.00707.2012.

Listen Now:

 Standard Podcasts [00:11:07m]: Play Now | Play in Popup | Download | Embeddable Player | Hits (Loading)

Can diabetes treatments also protect the heart? In our latest podcast we explore the work by Takahashi et al, which examined what a DPP-IV inhibitors will do at the level of the heart. Associate Editor Gary Lopaschuk interviews lead author Masanori Asakura (National Cerebral and Cardiovascular Center, Osaka, Japan) and expert Zam Kassiri (University of Alberta) about this exciting new work which pulls together aspects of metabolism, heart failure, anti-diabetic agents and cardioprotection. Listen and learn more.

Ayako Takahashi, Masanori Asakura, Shin Ito, Kyung-Duk Min, Kazuhiro Shindo, Yi Yan, Yulin Liao, Satoru Yamazaki, Shoji Sanada, Yoshihiro Asano, Hatsue Ishibashi-Ueda, Seiji Takashima, Tetsuo Minamino, Hiroshi Asanuma, Naoki Mochizuki, and Masafumi Kitakaze Dipeptidyl-Peptidase IV Inhibition Improves Pathophysiology of Heart Failure and Increases Survival Rate in Pressure-Overloaded Mice Am J Physiol Heart Circ Physiol, published online March 15, 2013, doi: 10.1152/ajpheart.00454.2012.

Listen Now:

 Standard Podcasts [10:49m]: Play Now | Play in Popup | Download | Embeddable Player | Hits (Loading)

Can an abnormal metaboreflex activation causing coronary constriction help to explain the reduced ability of the heart to increase cardiac performance in heart failure patients during exercise? While the metaboreflex has been studied for decades, new research by Coutsos et al in a chronic dog model of heart failure gives fresh insights on how ventricular function is improved by relieving vasoconstriction and thus enhancing coronary blood flow. Associate Editor Fabio Recchia interviews lead author Donal O’Leary (Wayne State University) and expert Antonio Crisafulli (University of Cagliari, Italy) about this interesting work and its potential clinical impact on heart failure patients.

Matthew Coutsos, Javier A. Sala-Mercado, Masashi Ichinose, ZhenHua Li, Elizabeth J. Dawe, and Donal S. O'Leary Muscle Metaboreflex-Induced Coronary Vasoconstriction Limits Ventricular Contractility During Dynamic Exercise in Heart Failure Am J Physiol Heart Circ Physiol, published online January 25, 2013, doi: 10.1152/ajpheart.00879.2012.

Listen Now:

 Standard Podcasts [10:42m]: Play Now | Play in Popup | Download | Embeddable Player | Hits (Loading)

How is Ca2+ cycling in the heart altered in cardiomyopathy in Duchenne muscular dystrophy? Does a lack of the cytoskeletal protein dystrophin cause a perturbation in communication between L-type calcium channels and mitochondria? In our latest podcast on the work by Viola et al., Associate Editor Meredith Bond hosts a discussion with lead author Livia Hool (The University of Western Australia) and expert Angela Dulhunty (Australian National University). We examine the effect of disruption of the myocyte cytoskeleton in the mdx mouse model. We address the role of the myocyte cytoskeleton in regulating communication between plasma membrane and mitochondria, and we tackle potential clinical applications for muscular dystrophy patients. Listen now.

Helena M. Viola, Stefan M. K. Davies, Aleksandra Filipovska, and Livia C. Hool L-type Ca2+ channel contributes to alterations in mitochondrial calcium handling in the mdx ventricular myocyte Am J Physiol Heart Circ Physiol, published online January 18, 2013, doi: 10.1152/ajpheart.00700.2012.

Listen Now:

 Standard Podcasts [09:49m]: Play Now | Play in Popup | Download | Embeddable Player | Hits (Loading)